Displaying 26–50 of 223 results for Paul Thomas, Managing Editor
Probabilistic rather than deterministic modeling is essential, says Quintiles Davis Walp.
Middle managers in pharma today have a tough, thankless jobbut someones got to do it, and many do it well.
Organizations with built-in risk management frameworks allow middle managers to thrive, says Scott Chizzo, Maxiom Groups president and chief consultant, in this exclusive interview.
Pharma's middle managers carry on despite a "damned if we do, damned if we don't" environment.
People generally dont resist change, says the Life Cycle Institute's Bill Wilder. They resist being changed when they don't know why.
Industry consultant Jane Chin examines what makes the jobs of pharmas middle managers so tough, and how they can succeed against the odds.
As pharma and biopharma companies deal with turbulent times, they look to a more sophisticated (and even real-time) secondary market to help manage equipment and assets. An industry expert surveys the scene, and provides smart shopping and selling advice, software
Steris Finn-Aqua has developed a new technology for the automatic decontamination of pharma/biopharma effluent.
At PDA 2011, at issue was whether current EMA guidelines are rational or risky; also, a look at new filtration products on the market.
With FDA and the Obama administration on alert, it is drug manufacturers' turn to address a crisis.
Elan's head of manufacturing, Kevin Brady, talks about what works, and why.
If it cant be measured, it cant be green; leading manufacturers are turning to advanced metrics to show just how sustainable their products, processes, and plants really are.
Theres nothing like a good tale of frugality to make your day.
Abbott's Continuous Improvement Manager shares best practices on how to prepare an organization for Lean and Six Sigma projects.
IT, Engineering, Lab? The answer under a consolidated system should be no one and everyone, says Patnis Jim Macdonell.
As paradigms shift, we also need paradigm expansion.
John Danese, Oracles Director of Product Strategy, provides an update on the electronic pedigree landscape and how manufacturers are doing in their serialization efforts.
Manufacturers electronic pedigree and serialization efforts creep ahead, slowed by FDAs inaction.
Maxiom Groups Scott Dicks answers our questions about whether drug manufacturers are moving ahead with electronic pedigree programs, software
The annual spring tradeshow has reenergized itself by building a year-round online presence.
Our annual survey results say youve just about had enough. Will 2011 be the year things turn in your favor?
Theres still not enough evidence for full-fledged optimism, says a leading recruiter.
Production planning is hard enough, but when uncertainty peaks, the challenges are compounded.
Customized, cheaper immunotherapies could be delivered to patients within a month, says Argos Therapeutics head of manufacturing.
Three experts share their views and best practices of risk-based contract partnerships.